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SUMMARY – Macrophage activation syndrome (MAS) is a potentially fatal complication of 
systemic juvenile idiopathic arthritis (sJIA), caused by exaggerated but ineff ective immune response. 
Th e aim of the study was to compare the capacity of the HLH-2004 guidelines with the capacity of 
the MAS guidelines from 2005, and with the new set of classifi cation criteria from 2016 in diagnosing 
MAS complicating sJIA. Th e study included 35 children aged 1-18 diagnosed with sJIA according to 
ILAR criteria and treated at the Department of Pediatrics, Division of Immunology and Rheumatol-
ogy, Zagreb University Hospital Centre, in the period from 2009 to 2015. Out of 35 patients diag-
nosed with sJIA, there were 12 girls and 23 boys, with the mean age at disease onset (±SD) 5.51±3.65 
years. Eight patients had fl are of disease. With the guidelines from 2005, MAS was diagnosed in six 
(17.1%) patients with sJIA. With the new set of classifi cation criteria from 2016, MAS was diagnosed 
in four (11.4%) patients with sJIA. MAS was not diagnosed with the HLH-2004 guidelines. In our 
study, four out of six patients had MAS at the onset of sJIA, and in the rest two it occurred during 
relapse. Two patients with MAS developed full-blown clinical picture while another four had incom-
plete clinical features with minor laboratory alteration. Due to the use of diff erent diagnostic guide-
lines, we found diff erence in the prevalence of MAS. It was slightly higher in comparison to available 
studies, while other researched features, such as clinical characteristics, were similar.
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Introduction
Macrophage activation syndrome (MAS) is a po-
tentially fatal complication of systemic juvenile idio-
pathic arthritis (sJIA), caused by an exaggerated but 
ineff ective immune response involving excessive mac-
rophage and T cell activation, followed by high pro-
duction of proinfl ammatory cytokines1-3. Th e cardinal 
clinical symptoms and signs are prolonged high fever, 
hepatosplenomegaly, neurologic dysfunction, and 
hemorrhagic manifestations. Characteristic laboratory 
abnormalities include pancytopenia, elevated levels of 
serum liver enzymes, triglycerides, lactate dehydroge-
nase, ferritin, and low levels of fi brinogen. Although 
macrophage hemophagocytosis is often seen on bone 
marrow examination, in the initial stages of the syn-
drome this fi nding may be absent4,5. Th e reported mor-
tality rates of MAS reach 20%-30%, but the outcome 
can be improved by early diagnosis and prompt initia-
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tion of life-saving treatment3. Th e estimated preva-
lence of MAS in sJIA is 10%. However, recent evi-
dence suggests that the syndrome may occur subclini-
cally in an additional 30%-40% of sJIA patients6,7. 
Because MAS is similar to the group of histiocytic 
disorders belonging to hemophagocytic lymphohistio-
cytosis (HLH), it is currently classifi ed among the sec-
ondary, or acquired, forms of HLH8,9. Th ree sets of 
guidelines are currently available for diagnosing MAS 
in patients with sJIA, as follows: diagnostic guidelines 
for HLH (HLH-2004), which were primarily devel-
oped for homozygous genetic disorders10; preliminary 
diagnostic guidelines for MAS complicating sJIA 
from 200511; and the new set of classifi cation criteria 
for MAS complicating sJIA from 2016, based on a 
combination of expert consensus, available evidence 
from medical literature, and analysis of real patient 
data12.
Patients and Methods
A retrospective study was carried out at the De-
partment of Pediatrics, Division of Immunology and 
Rheumatology, Zagreb University Hospital Centre, in 
the period from 2009 to 2015. Th e study included 35 
children aged 1-18 diagnosed with sJIA according to 
ILAR criteria13. Epidemiological and clinical data 
were obtained from patient records. Demographic in-
formation included gender, date of birth, age at onset 
of sJIA and age at onset of MAS. Clinical data in-
cluded fever, hepatomegaly, splenomegaly, hemorrhag-
ic manifestations, lymphadenopathy, active arthritis, 
central nervous system (CNS) involvement and serosi-
tis. Extensive laboratory workup was performed on all 
patients (erythrocyte sedimentation rate (ESR), C-re-
active protein (CRP), complete blood count, aspartate 
aminotransferase (AST), alanine aminotransferase, fi -
Table 1. Clinical features and laboratory values of patients with systemic juvenile idiopathic arthritis (sJIA), 





Systemic JIA with MAS
n (6)
Fever 35/35 8/8 6/6
Arthritis 35/35 6/8 1/6




Hepatomegaly 8/35 4/8 5/6 
Splenomegaly 4/35 1/8 1/6 
Serositis 3/35 0 1/6
Hemorrhages 0 0 1/6
CNS involvement 0 0 0
CRP (mg/L) 132.2 (31.7-320.8) 59 (25-124) 123 (65-431.4)
ESR (mm/h) 81 (32-142) 39 (25-70) 27.5 (14-55)
Hemoglobin (g/dL) 108 (77-130) 118 (87-128) 105 (87-127)
WBC (x109/L) 16.6 (9.6-44.8) 13.8 (7.6-24.8) 6.1 (4.0-7.4)
Platelets (x109/L) 436 (275-868) 322 (204-371) 177 (124-271)
Fibrinogen (g/L) 6.7 (5.1-8.4) 5.5 (3.6-6.2) 3.3 (2.1-4.2)
D-dimer (mg/L) 2.8 (0.8-14.2) 2.3 (0.33-5.9) 5.5 (1.4-45.6)
Ferritin (μg/L) 412 (129.9-9843) 570 (173.7-11229) 3531(783-20000)
AST (U/L) 28 (15-61) 42 (15-74) 66 (26-210)
Triglycerides (mmol/L) 1.30 (0.53-1.87) 1.29 (1.18-1.90) 2.09 (1.29-3.92)
CNS = central nervous system; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; WBC = white blood cell count; 
AST = aspartate aminotransferase
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brinogen, D-dimer levels, ferritin, triglycerides, and 
immunologic parameters including anti-nuclear anti-
bodies by indirect immunofl uorescence and rheuma-
toid factor). Quantitative data are presented as median 
with interquartile range, and categorical data are pre-
sented as absolute number. An Ethics Committee ap-
proval was obtained before data collection.
Results
Systemic JIA was diagnosed in 35 children, 23 boys 
and 12 girls, mean age (±SD) 5.51±3.65 years. Eight of 
35 patients had fl are of sJIA. At the disease onset, all 
patients presented with fever, evanescent rash and ar-
thritis. Th e most consistent symptoms were hepato-
megaly (8/35) and splenomegaly (4/35). All patients 
with fl are of sJIA also presented with fever and eva-
nescent rash, and half of them had hepatomegaly. In-
fl ammation markers (ESR and CRP) were elevated in 
all patients at disease onset and in fl are (Table 1).
With the use of guidelines from 2005, MAS was 
diagnosed in six (6/35, 17.1%) patients with sJIA. In 
four of them, it occurred at the onset of sJIA during 
fi rst hospitalization and in the remaining two patients, 
it occurred during fl are. With the new set of criteria 
from 2016, MAS was diagnosed in four (4/35, 11.4%) 
patients with sJIA. In three of them, it occurred during 
fi rst hospitalization, and in one patient it occurred 
during fl are. MAS was not diagnosed with the HLH-
2004 guidelines. Fever (6/6) and hepatomegaly (5/6) 
were the most common clinical criteria recorded in 
patients with MAS, followed by splenomegaly and 
hemorrhages. CNS dysfunction was not recorded. All 
laboratory values were abnormal, as expected (showing 
either increased or decreased levels) in patients with 
MAS when compared with sJIA patients (Table 1).
Discussion
We compared the capacity of HLH-2004 guide-
lines with the capacity of MAS guidelines from 2005, 
and with the new ones from 2016 as diagnostic tools 
for MAS associated with sJIA. With the new set of 
criteria from 2016, the prevalence of MAS was 11.4% 
(4/35) and with the guidelines from 2005 the preva-
lence of MAS was 17.1% (6/35). HLH-2004 guide-
lines did not record MAS at all. Th is is consistent with 
literature data where the prevalence of MAS in sJIA is 
10%, and with recent evidence suggesting the possibil-
ity of subclinical occurrence in an additional 30%-40% 
of sJIA patients6,7.
Macrophage activation syndrome generally devel-
ops in earlier phases of the underlying disease, or may 
be the presenting manifestation of sJIA. In our study, 
four out of six patients had MAS at the onset of sJIA, 
during fi rst hospitalization, and in two out of six pa-
tients it occurred during fl are.
Typically, patients with MAS become acutely ill 
with sudden onset of nonremitting high fever, pro-
found depression in all 3 blood cell lines (i.e. leukope-
nia, anemia and thrombocytopenia), hepatospleno-
megaly, lymphadenopathy, and elevated serum liver 
enzyme levels. In our study, two of 35 patients had 
full-blown clinical picture of MAS, with laboratory 
test values in line with expectations, showing absolute 
decline and typical changes that occur in the syn-
drome. Another four of 35 patients had incomplete 
clinical features and relative decline in these laboratory 
parameters in comparison with sJIA patients.
Clinical symptoms are often delayed or similar to 
confusable conditions such as infections, sepsis and 
fl are of underlying disease. Comparing the criteria, it is 
obvious that the majority of our patients satisfi ed the 
criteria from 2005, which include clinical manifesta-
tions such as hepatomegaly and hemorrhages. Notably, 
fi ve out of six patients with MAS had hepatomegaly. 
However, hepatomegaly was present in half (4/8) of 
patients with sJIA fl are and in eight (8/35) patients at 
the onset of sJIA, probably because mild hepatomega-
ly is a frequent feature of active sJIA.
Th e prevalence of all laboratory MAS criteria was 
much greater in patients with MAS comparing to 
sJIA. Hyperferritinemia is an important laboratory 
hallmark of MAS, therefore, it is mandatory in the 
new set of classifi cation criteria (ferritin >684 ng/mL). 
In our study, patients with MAS had signifi cantly in-
creased ferritin levels; they all met the previously men-
tioned condition, whereas patients at the onset of sJIA 
and fl are of sJIA did not. In the new set of MAS crite-
ria, platelet count and fi brinogen levels are within the 
normal range of laboratory tests and the levels of AST 
and triglycerides are only slightly above the normal 
limits. In contrast, children with active sJIA usually 
have signifi cantly increased platelet counts and fi brin-
ogen levels, and normal levels of AST and triglycer-
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ides12,14. In our study, most of the MAS patients had 
slightly decreased  platelet count, slightly increased 
AST and triglycerides, while the levels of fi brinogen 
and leukocytes were within the normal range.
Our results should be interpreted in the light of 
some potential limitations, primarily the small number 
of MAS patients. However, we would like to point out 
that we were dealing with the disease that is not con-
sidered common. Patient data were collected through 
retrospective review of clinical charts. We had incom-
plete laboratory data for triglycerides and fi brinogen, 
which both are part of the guidelines.
In conclusion, due to the use of diff erent diagnostic 
guidelines, we found a diff erence in the prevalence of 
MAS. It was slightly higher in comparison to available 
studies, while other investigated features, such as clini-
cal characteristics, were similar. It is important to make 
a timely diagnosis of MAS, usually by clinical expert 
opinion and detection of subtle laboratory alterati on 
before the occurrence of full-blown clinical picture 
which, if untreated, leads to fatal outcome.
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Sažetak
USPOREDBA RAZLIČITIH DIJAGNOSTIČKIH SMJERNICA 
ZA DIJAGNOZU SINDROMA AKTIVACIJE MAKROFAGA KOJI KOMPLICIRA 
SISTEMSKI TIP JUVENILNOG IDIOPATSKOG ARTRITISA: ISKUSTVO JEDNOG CENTRA
M. Jelušić, M. Kronja, M. Frković, S. Sršen, S. Huljev Frković i K. Štekić Novački
Sindrom aktivacije makrofaga (MAS) potencijalno je smrtonosna komplikacija sistemskog tipa juvenilnog idiopatskog 
artritisa (sJIA) uzrokovana prekomjernim, ali neučinkovitim imunim odgovorom. Cilj ovoga istraživanja bio je usporediti 
dijagnostičku mogućnost smjernica HLH-2004 sa smjernicama za MAS iz 2005. godine, kao i s novim skupom klasifi kacij-
skih kriterija iz 2016. godine u dijagnostici MAS-a koji komplicira sJIA. U istraživanje je bilo uključeno 35 djece u dobi od 
1 do 18 godina kojima je postavljena dijagnoza sJIA prema kriterijima ILAR-a i koja su liječena u Klinici za pedijatriju, 
Zavodu za imunologiju i reumatologiju Kliničkog bolničkog centra Zagreb u razdoblju od 2009. do 2015. godine. Od 35 
bolesnika kojima je postavljena dijagnoza sJIA bilo je 12 djevojčica i 23 dječaka koji su u vrijeme početka bolesti bili prosječ-
ne dobi (±SD) 5,51±3,65 godina. Osmero bolesnika imalo je recidiv bolesti. Prema smjernicama iz 2005. godine dijagnoza 
MAS-a postavljena je u šestero (17,1%) bolesnika sa sJIA. Prema novom skupu klasifi kacijskih kriterija iz 2016. godine 
 dijagnoza MAS-a postavljena je u četvero (11,4%) bolesnika sa sJIA. Dijagnoza MAS-a nije postavljena ni u jednog bole-
snika prema smjernicama HLH-2004. U našem istraživanju četvero od šestero bolesnika imalo je MAS na početku sJIA, a u 
preostalih dvoje on se pojavio tijekom recidiva bolesti. Dvoje bolesnika s MAS-om razvilo je punu kliničku sliku bolesti, dok 
ih je preostalih četvoro imalo nepotpuna klinička obilježja s manjim odstupanjem u laboratorijskim nalazima. Primjenom 
različitih dijagnostičkih smjernica utvrdili smo razliku u učestalosti MAS-a. Učestalost je bila nešto viša u usporedbi s posto-
jećim istraživanjima, dok su ostala istraživana obilježja poput kliničkih karakteristika bila slična.
Ključne riječi: sindrom aktivacije makrofaga; artritis, juvenilni; dijete; Hrvatska; limfohistiocitoza, hemofagocitična
